Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

An analysis of the clinical and biologic significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma.

Xiong W, Wu X, Starnes S, Johnson SK, Haessler J, Wang S, Chen L, Barlogie B, Shaughnessy JD Jr, Zhan F.

Blood. 2008 Nov 15;112(10):4235-46. doi: 10.1182/blood-2007-10-119123. Epub 2008 Mar 12.

2.

Integrative genomics revealed RAI3 is a cell growth-promoting gene and a novel P53 transcriptional target.

Wu Q, Ding W, Mirza A, Van Arsdale T, Wei I, Bishop WR, Basso A, McClanahan T, Luo L, Kirschmeier P, Gustafson E, Hernandez M, Liu S.

J Biol Chem. 2005 Apr 1;280(13):12935-43. Epub 2005 Jan 18.

3.
4.

A comprehensive assessment of p53-responsive genes following adenoviral-p53 gene transfer in Bcl-2-expressing prostate cancer cells.

Spurgers KB, Coombes KR, Meyn RE, Gold DL, Logothetis CJ, Johnson TJ, McDonnell TJ.

Oncogene. 2004 Mar 4;23(9):1712-23.

PMID:
14647426
5.

Molecular and transcriptional characterization of 17p loss in B-cell chronic lymphocytic leukemia.

Fabris S, Mosca L, Todoerti K, Cutrona G, Lionetti M, Intini D, Matis S, Colombo M, Agnelli L, Gentile M, Spriano M, Callea V, Festini G, Molica S, Lambertenghi Deliliers G, Morabito F, Ferrarini M, Neri A.

Genes Chromosomes Cancer. 2008 Sep;47(9):781-93. doi: 10.1002/gcc.20579.

PMID:
18521849
6.

Prediction of breast cancer prognosis by gene expression profile of TP53 status.

Takahashi S, Moriya T, Ishida T, Shibata H, Sasano H, Ohuchi N, Ishioka C.

Cancer Sci. 2008 Feb;99(2):324-32. doi: 10.1111/j.1349-7006.2007.00691.x.

7.
8.

Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis.

Davies FE, Dring AM, Li C, Rawstron AC, Shammas MA, O'Connor SM, Fenton JA, Hideshima T, Chauhan D, Tai IT, Robinson E, Auclair D, Rees K, Gonzalez D, Ashcroft AJ, Dasgupta R, Mitsiades C, Mitsiades N, Chen LB, Wong WH, Munshi NC, Morgan GJ, Anderson KC.

Blood. 2003 Dec 15;102(13):4504-11. Epub 2003 Aug 28.

9.

Molecular genetic studies of tumor suppressor gene regions on chromosomes 13 and 17 in colorectal tumors.

Lothe RA, Fossli T, Danielsen HE, Stenwig AE, Nesland JM, Gallie B, Børresen AL.

J Natl Cancer Inst. 1992 Jul 15;84(14):1100-8.

PMID:
1619684
10.

RITA (Reactivating p53 and Inducing Tumor Apoptosis) is efficient against TP53abnormal myeloma cells independently of the p53 pathway.

Surget S, Descamps G, Brosseau C, Normant V, Maïga S, Gomez-Bougie P, Gouy-Colin N, Godon C, Béné MC, Moreau P, Le Gouill S, Amiot M, Pellat-Deceunynck C.

BMC Cancer. 2014 Jun 14;14:437. doi: 10.1186/1471-2407-14-437.

11.

Cancer/testis genes in multiple myeloma: expression patterns and prognosis value determined by microarray analysis.

Condomines M, Hose D, Raynaud P, Hundemer M, De Vos J, Baudard M, Moehler T, Pantesco V, Moos M, Schved JF, Rossi JF, Rème T, Goldschmidt H, Klein B.

J Immunol. 2007 Mar 1;178(5):3307-15.

12.

Identification of cell cycle regulatory genes as principal targets of p53-mediated transcriptional repression.

Spurgers KB, Gold DL, Coombes KR, Bohnenstiehl NL, Mullins B, Meyn RE, Logothetis CJ, McDonnell TJ.

J Biol Chem. 2006 Sep 1;281(35):25134-42. Epub 2006 Jun 23.

13.

Cyclin D1 overexpression is not a specific grouping marker, but may collaborate with CDC37 in myeloma cells.

Katayama Y, Sakai A, Okikawa Y, Oue N, Asaoku H, Sasaki A, Imanaka F, Tsujimoto T, Takimoto Y, Masuda R, Nakaju N, Otsuki T, Yasui W, Kimura A.

Int J Oncol. 2004 Sep;25(3):579-95.

PMID:
15289859
14.

Microarray analysis of p53-dependent gene expression in response to hypoxia and DNA damage.

Corn PG, El-Deiry WS.

Cancer Biol Ther. 2007 Dec;6(12):1858-66. Epub 2007 Nov 20.

PMID:
18087215
15.

SAGE analysis highlights the importance of p53csv, ddx5, mapkapk2 and ranbp2 to multiple myeloma tumorigenesis.

Felix RS, Colleoni GW, Caballero OL, Yamamoto M, Almeida MS, Andrade VC, Chauffaille Mde L, Silva WA Jr, Begnami MD, Soares FA, Simpson AJ, Zago MA, Vettore AL.

Cancer Lett. 2009 Jun 8;278(1):41-8. doi: 10.1016/j.canlet.2008.12.022. Epub 2009 Jan 25.

PMID:
19171422
16.

A molecular compendium of genes expressed in multiple myeloma.

Claudio JO, Masih-Khan E, Tang H, Gonçalves J, Voralia M, Li ZH, Nadeem V, Cukerman E, Francisco-Pabalan O, Liew CC, Woodgett JR, Stewart AK.

Blood. 2002 Sep 15;100(6):2175-86.

17.

miR-34a as part of the resistance network in chronic lymphocytic leukemia.

Zenz T, Mohr J, Eldering E, Kater AP, Bühler A, Kienle D, Winkler D, Dürig J, van Oers MH, Mertens D, Döhner H, Stilgenbauer S.

Blood. 2009 Apr 16;113(16):3801-8. doi: 10.1182/blood-2008-08-172254. Epub 2008 Oct 21.

18.

Integrative high-resolution microarray analysis of human myeloma cell lines reveals deregulated miRNA expression associated with allelic imbalances and gene expression profiles.

Lionetti M, Agnelli L, Mosca L, Fabris S, Andronache A, Todoerti K, Ronchetti D, Deliliers GL, Neri A.

Genes Chromosomes Cancer. 2009 Jun;48(6):521-31. doi: 10.1002/gcc.20660.

PMID:
19306352
19.

A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients.

Alsner J, Jensen V, Kyndi M, Offersen BV, Vu P, Børresen-Dale AL, Overgaard J.

Acta Oncol. 2008;47(4):600-7. doi: 10.1080/02841860802047411.

PMID:
18465328
20.

Expression profiling of t(12;22) positive clear cell sarcoma of soft tissue cell lines reveals characteristic up-regulation of potential new marker genes including ERBB3.

Schaefer KL, Brachwitz K, Wai DH, Braun Y, Diallo R, Korsching E, Eisenacher M, Voss R, Van Valen F, Baer C, Selle B, Spahn L, Liao SK, Lee KA, Hogendoorn PC, Reifenberger G, Gabbert HE, Poremba C.

Cancer Res. 2004 May 15;64(10):3395-405.

Supplemental Content

Support Center